BR0209646A - genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos - Google Patents

genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos

Info

Publication number
BR0209646A
BR0209646A BRPI0209646-3A BR0209646A BR0209646A BR 0209646 A BR0209646 A BR 0209646A BR 0209646 A BR0209646 A BR 0209646A BR 0209646 A BR0209646 A BR 0209646A
Authority
BR
Brazil
Prior art keywords
breast
prognostic
methods
breast carcinoma
therapeutic targets
Prior art date
Application number
BRPI0209646-3A
Other languages
English (en)
Inventor
Marlene Michelle Dressman
Christian Nicolas Lavedan
Mihael Polymeropoulos
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0209646A publication Critical patent/BR0209646A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"GENES EXPRESSOS EM CáNCER DE MAMA COMO ALVOS DE PROGNóSTICO E TERAPêUTICO". A invenção refere-se a métodos para determinação da responsividade endócrina de carcinoma de mama e tratamento e monitoramento da progressão do carcinoma de mama baseado em genes que são diferencialmente expressos em tumores de mama. São também descritos métodos para identificação de agentes úteis no tratamento de carcinoma de mama, métodos para monitoramento da eficácia de um tratamento para carcinoma de mama, métodos para inibição da proliferação de um carcinoma de mama, e vetores específicos, de mama, incluindo os promotores dos genes descritos.
BRPI0209646-3A 2001-05-16 2002-04-11 genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos BR0209646A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29142801P 2001-05-16 2001-05-16
PCT/US2002/011313 WO2002092854A2 (en) 2001-05-16 2002-04-11 Genes expressed in breast cancer as prognostic and therapeutic targets

Publications (1)

Publication Number Publication Date
BR0209646A true BR0209646A (pt) 2006-10-10

Family

ID=23120250

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0209646-3A BR0209646A (pt) 2001-05-16 2002-04-11 genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos

Country Status (7)

Country Link
US (1) US20030064385A1 (pt)
EP (1) EP1399593A2 (pt)
JP (1) JP2005512510A (pt)
CN (1) CN1526025A (pt)
BR (1) BR0209646A (pt)
CA (1) CA2443627A1 (pt)
WO (1) WO2002092854A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068636A1 (en) * 2001-06-21 2003-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
EP2241636A1 (en) * 2002-03-13 2010-10-20 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
WO2005007892A1 (en) * 2003-07-03 2005-01-27 Gentron, Llc Methods and systems for diagnosis of non-cenral nervous system (cns) diseases in cns samples
MXPA06001327A (es) * 2003-08-07 2006-05-04 Chiron Corp Factor trefoil3 (tff3) como objetivo para terapia anti-cancer.
US20050221383A1 (en) * 2003-08-08 2005-10-06 Choong-Chin Liew Osteoarthritis biomarkers and uses thereof
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
GB0320648D0 (en) * 2003-09-03 2003-10-01 Randox Lab Ltd Molecular marker
BRPI0416925A (pt) * 2003-11-25 2007-01-16 Novartis Ag biomarcadores para a eficácia de tratamento com análogo de somatostatina
BRPI0416945A (pt) * 2003-11-25 2007-02-13 Novartis Ag biomarcadores para a eficácia do tratamento com hormÈnio paratiróide e calcitonina
US20050260659A1 (en) * 2004-04-23 2005-11-24 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
CA2568732A1 (en) * 2004-06-03 2005-12-15 Bayer Healthcare Ag Methods for predicting and monitoring response to cancer therapy
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
US20060177837A1 (en) * 2004-08-13 2006-08-10 Ivan Borozan Systems and methods for identifying diagnostic indicators
US9109256B2 (en) * 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
EP1742059A1 (en) * 2004-12-09 2007-01-10 DIGILAB BioVisioN GmbH Use of PTA peptides for stratification of individuals having cancer
WO2006108135A2 (en) * 2005-04-04 2006-10-12 Veridex, Llc Laser microdissection and microarray analysis of breast tumors reveal estrogen receptor related genes and pathways
KR20080073711A (ko) * 2005-10-21 2008-08-11 바이엘 헬스케어 엘엘씨 암의 예측 및 예후 방법, 및 암 치료 모니터링 방법
US20080108065A1 (en) * 2006-04-28 2008-05-08 Indra Poola Systems and diagnostic methods for breast cancer using mmp-1 markers
CN101743476A (zh) * 2006-10-03 2010-06-16 尼瑞医药品有限公司 结合三叶因子的构象特异性抗体以及使用该抗体治疗癌症以及增殖疾病的方法
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
CN102395682B (zh) * 2007-09-06 2015-09-30 生物治疗诊断股份有限公司 肿瘤分级和癌症预后
WO2009089102A2 (en) * 2008-01-02 2009-07-16 Fox Chase Cancer Center Identification and characterization of pregnancy- associated genetic signatures and use thereof for diagnosis and treatment of breast cancer
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
EP2253715A1 (en) * 2009-05-14 2010-11-24 RWTH Aachen New targets for cancer therapy and/or diagnosis
US8735548B2 (en) 2010-06-30 2014-05-27 Amgen Inc. Antibodies which bind to SCNN1A/TNFRSF1A fusion proteins and methods of use thereof
JP7144934B2 (ja) 2015-03-25 2022-09-30 ザ ジェネラル ホスピタル コーポレイション 血液試料中の循環腫瘍細胞のデジタル分析
CA2982169A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
EP3532642B1 (en) * 2016-10-27 2021-12-08 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
TN2019000308A1 (en) 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
TW202022124A (zh) * 2018-08-17 2020-06-16 瑞士商赫孚孟拉羅股份公司 用於治療乳癌的診斷及治療方法
CN109735625A (zh) * 2019-03-18 2019-05-10 马榕 乳头溢液在检测肿瘤相关基因中的应用
CN110358829A (zh) * 2019-07-09 2019-10-22 江苏医药职业学院 检测重组人肽基脯氨酰顺反异构酶-h表达水平的试剂的应用和试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1796492A (en) * 1991-04-25 1992-12-21 Sloan-Kettering Institute For Cancer Research Antigen recognized by antibodies associated with paraneoplastic opsoclonus and methods of use thereof
CA2132500A1 (en) * 1994-09-20 1996-03-21 David Lockwood Manning Methods for predicting the behaviour of breast tumours

Also Published As

Publication number Publication date
US20030064385A1 (en) 2003-04-03
WO2002092854A2 (en) 2002-11-21
JP2005512510A (ja) 2005-05-12
CN1526025A (zh) 2004-09-01
WO2002092854A3 (en) 2004-01-15
CA2443627A1 (en) 2002-11-21
EP1399593A2 (en) 2004-03-24

Similar Documents

Publication Publication Date Title
BR0209646A (pt) genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos
ATE425749T1 (de) Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
NO20000752D0 (no) Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser
BR0316229A (pt) Métodos de tratamento de câncer e métodos relacionados
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
WO2001051628A3 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2002071928A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
PT1581812E (pt) Composições e métodos para diagnóstico e tratamento de cancros do cólon
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
PT99562A (pt) Metodo para o diagnostico de tumores malignos atraves da deteccao de estromelis ina-3
WO2002059373A3 (en) Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
WO2003009814A3 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
WO2001042467A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2008073629A3 (en) Bifunctional predictors of cancer treatment sensitivity and resistance
BR9807418A (pt) Terapia de gene supressor de tumor combinado e quimioterapia no tratamento de neoplasmas
EP0756488A4 (en) TUMOR SUPPRESSOR GENE AND METHOD FOR DETECTING CANCER
WO2001046697A3 (en) Identification, assessment, prevention, and therapy of breast cancer
EP1326996A4 (en) ID-1 AND ID-2 GENES AND PRODUCTS AS DIAGNOSTIC OR PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS FOR THE TREATMENT OF BREAST CANCER AND OTHER TYPES OF CARCINOMA
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
NO20002412D0 (no) FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler
WO2005027712A3 (en) Methods of diagnosing, prognosing and treating breast cancer
DE60032333D1 (de) Zusammensetzungen und verfahren zur intraductalen gentherapie

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.